vimarsana.com

Latest Breaking News On - Inderes event studio - Page 1 : vimarsana.com

In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO s Mode of Action

/PRNewswire/ Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that it will hold an in-person and virtual.

United statesUnited kingdomJonathan barrattGarethj thomasGareth thomasAmerican society of nephrology kidney health initiativeUniversity of leicesterIga nephropathy networkRenal research groupPhd university hospital southamptonUniversity of southamptonLife sciencesRare disease groupInderes event studioUniversity hospital southamptonExperimental pathology

Calliditas Therapeutics: In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO s Mode of Action

STOCKHOLM, May 16, 2024 /PRNewswire/ Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that it will hold an in-person and virtual R&D day

United statesUnited kingdomJonathan barrattGarethj thomasGareth thomasPhd university hospital southamptonRenal research groupLife sciencesUniversity of leicesterAmerican society of nephrology kidney health initiativeIga nephropathy networkUniversity of southamptonRare disease groupInderes event studioUniversity hospital southamptonExperimental pathology

In Person & Virtual R&D Day: The Anti Fibrotic Effects of Setanaxib and TARPEYO s Mode of Action

English .

United kingdomUnited statesJonathan barrattGarethj thomasGareth thomasRenal research groupUniversity of southamptonIga nephropathy networkExchange commissionAmerican society of nephrology kidney health initiativeRare disease groupLife sciencesUniversity of leicesterCompany news systemPhd university hospital southamptonVirtual rd day

Mendus provides business update and outlook for vididencel program

Press Release Stockholm, Sweden, March 12, 2024 ADVANCE II Phase 2 trial data provide basis for late-stage development of lead product vididencel in acute myeloid leukemiaRegistration trial.

United statesErik mantingLymphoma groupAmerican society for hematologyNorthx biologicsBusiness updateAmerican societyAustralian leukemiaInderes event studioNasdaq stockholm

Mendus to hold Business Update event on March 12

23.02.2024 - Press Release Stockholm, Sweden, February 23, 2024 Mendus AB (“Mendus” publ; IMMU.ST), will hold an in-person and live-streamed business update event in Stockholm on March 12, 15:00-17:00 CET to discuss the company’s latest pipeline .

Erik mantingLymphoma groupNorthx biologicsInderes event studioMendus chartEndus kursEndus aktie

vimarsana © 2020. All Rights Reserved.